AVROBIO INC (AVRO) Stock News
NASDAQ:AVRO - Nasdaq - US05455M1009 - Common Stock - Currency: USD
AVRO Latest News, Press Relases and Analysis
PLTR Stock: Palantir Bags New Partnership With ARPA-H for AI/ML
Palantir stock is on the rise Thursday as PLTR investors react to a new $19 million contract for the big data and AI company.
Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?
NLS Pharmaceutics stock is down on Thursday as shares of NLSP come off of a recent rally that was fueled by heavy trading on Tuesday.
Why Is Avrobio (AVRO) Stock Moving Today?
Avrobio stock is in the news Thursday as the company prepares for a merger and reverse stock split of AVRO after markets close today.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Thursday and we have all the hottest news behind these movements this morning!
AVRO Stock Earnings: Avrobio Beats EPS for Q1 2024
AVRO stock results show that Avrobio beat analyst estimates for earnings per share the first quarter of 2024.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWN, INBX, AVRO
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Why Avrobio Shares Are Rising Wednesday
AVROBIO Inc (NASDAQ: AVRO) shares are trading higher Wednesday after the company said it will explore strategic alternatives.
AVROBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO
Kuehn Law Encourages CHRD, AVRO, KAMN, and CTLT Investors to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CALB, AVRO, GLT, FREE
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Why Is AVROBIO (AVRO) Stock Up 83% Today?
AVROBIO (AVRO) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NVS).
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates GMGI, KRTX, SIX, AVRO
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO
INVESTIGATION ALERT: Halper Sadeh LLC Investigates AVRO, CSTR, BBAI, PGTI
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Kuehn Law Encourages ICVX, CSTR, AVRO, and CALB Investors to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
Shareholder Alert: Ademi LLP investigates whether AVROBIO, Inc. has obtained a Fair Price in its transaction with Tectonic
/PRNewswire/ -- Ademi LLP is investigating AVROBIO, Inc. (Nasdaq: AVRO) for possible breaches of fiduciary duty and other violations of law in its transaction...
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AVRO, CALB, BCAL
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
AVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of AVROBIO, Inc. Is Fair to Shareholders
Avrobio to buy 100% equity interests of Tectonic Therapeutic (NASDAQ:AVRO)
AVROBIO plans to acquire biotech company Tectonic Therapeutic, resulting in combined ownership percentages and a cash infusion to advance their pipeline.
AVROBIO and Tectonic Therapeutic Announce Merger
Avrobio to explore strategic options; halts studies (NASDAQ:AVRO)
Avrobio, Inc. (AVRO) announced Wednesday its plans to explore strategic alternatives and halt further advancement of its drug development programs. Read more here.
AVROBIO to Explore Strategic Alternatives
Avrobio completes sale of gene therapy program to Novartis for $87.5M (AVRO)
Avrobio (AVRO) has completed the sale of its cystinosis gene therapy program to Novartis (NVS) for $87.5M in cash, which should extend its cash runway into Q4 2024. Read more here.
Mentions: NVS
AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million
